Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study.

Saved in:
Bibliographic Details
Title: Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study.
Authors: Chang YS; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Liu CY; Institute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan., Chen YW; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan., Huang SH; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan., Lin HY; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan., Lin CC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tsai XC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tien FM; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Cheng CL; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Yuan CT; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan., Kuo YY; Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan., Ko BS; Department of Hematological Oncology, National Taiwan, University Cancer Center, Taipei, Taiwan., Yao M; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Division of Cellular Therapy, Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan., Tien HF; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei City, Taiwan., Chou WC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Hou HA; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Division of General Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: hsinanhou@ntu.edu.tw.
Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2025 Dec; Vol. 25 (12), pp. 885-896. Date of Electronic Publication: 2025 Jun 25.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2152-2669
DOI:10.1016/j.clml.2025.06.011